US-based Stryker (NYSE: SYK) has reached a definitive acquisition agreement with compatriot firm Inari Medical, Inc. (NASDAQ: NARI), purchasing all issued and outstanding shares at USD 80 per share in cash. The transaction amounts to a total fully diluted equity value of approximately USD 4.9 billion.
Inari Medical’s Portfolio
Founded in 2011, Inari Medical boasts an innovative peripheral vascular product portfolio that is highly complementary to Stryker’s Neurovascular business. The company’s products cover mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism.
Significance of the Acquisition
The deal, expected to close during the first quarter of this year, is anticipated to significantly enhance Stryker’s venous thromboembolism (VTE) pipeline. By integrating Inari Medical’s innovative solutions, Stryker aims to expand its offerings in the treatment of VTE, providing more comprehensive and effective solutions to healthcare providers and patients.-Fineline Info & Tech
